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Abstract
Background: Premature birth is the major cause of perinatal mortality and morbidity in both high- and low-income
countries. The causes of preterm labour are multiple but infection is important. We have previously described an unusually
high incidence of preterm birth (20%) in an ultrasound-dated, rural, pregnant population in Southern Malawi with high
burdens of infective morbidity. We have now studied the impact of routine prophylaxis with azithromycin as directly
observed, single-dose therapy at two gestational windows to try to decrease the incidence of preterm birth.
Methods and Findings: We randomized 2,297 pregnant women attending three rural and one peri-urban health centres in
Southern Malawi to a placebo-controlled trial of oral azithromycin (1 g) given at 16–24 and 28–32 wk gestation. Gestational
age was determined by ultrasound before 24 wk. Women and their infants were followed up until 6 wk post delivery. The
primary outcome was incidence of preterm delivery, defined as,37 wk. Secondary outcomes were mean gestational age at
delivery, perinatal mortality, birthweight, maternal malaria, and anaemia. Analysis was by intention to treat. There were no
significant differences in outcome between the azithromycin group (n= 1,096) and the placebo group (n= 1,087) in respect
of preterm birth (16.8% versus 17.4%), odds ratio (OR) 0.96, 95% confidence interval (0.76–1.21); mean gestational age at
delivery (38.5 versus 38.4 weeks), mean difference 0.16 (20.08 to 0.40); mean birthweight (3.03 versus 2.99 kg), mean
difference 0.04 (20.005 to 0.08); perinatal deaths (4.3% versus 5.0%), OR 0.85 (0.53–1.38); or maternal malarial parasitaemia
(11.5% versus 10.1%), OR 1.11 (0.84–1.49) and anaemia (44.1% versus 41.3%) at 28–32 weeks, OR 1.07 (0.88–1.30). Meta-
analysis of the primary outcome results with seven other studies of routine antibiotic prophylaxis in pregnancy (.6,200
pregnancies) shows no effect on preterm birth (relative risk 1.02, 95% confidence interval 0.86–1.22).
Conclusions: This study provides no support for the use of antibiotics as routine prophylaxis to prevent preterm birth in
high risk populations; prevention of preterm birth requires alternative strategies.
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Introduction
Of the 4 million neonatal deaths each year, 99% occur in low-
income countries and 28% are attributable to preterm birth [1].
Preterm delivery is one of the nine main causes of death in
children below the age of 5 y [2]. Reducing the incidence of
prematurity is important if Millennium Development Goal 4 for
child survival (MDG-4) is to be achieved [2,3] and important to
reduce health service costs [4].
The incidence of preterm birth (before 37 completed wk of
pregnancy) is between 5% and 10% in most industrialised countries
[5]. A recently reported rise in preterm birth among primigravid
women in Denmark from 3.8% to 5.7% [6] caused sufficient concern
to merit an accompanying editorial [7]. The incidence of preterm
birth is higher in the United States—rising from 10.7% in 1992 to
12.3% in 2003 [8]. Estimates in low-income countries are difficult
because of common uncertainties about gestational age. However, we
have previously reported much higher rates of 24% (95% confidence
interval [CI] 21%–28%) and 20% (95% CI 17%–24%) in rural,
community-based, ultrasound-dated studies in Malawi of, respective-
ly, anaemic [9] and unselected [10] pregnant women. We are not
aware of any other similar, rural studies from sub-Saharan Africa,
although an urban study in Mozambique (using ultrasound) reported
an incidence of 15% [11].
The causes of preterm labour are multiple, and the processes
that ultimately lead to preterm birth may start many weeks before
labour starts [12,13]. There is compelling evidence for the
etiological importance of infection, mainly ascending genital tract
infection, and principally in association with earlier rather than
later preterm birth [14,15]. There is considerable evidence to
suggest that intrauterine infection may occur quite early in
pregnancy but remain undetected for months [14]. For example,
women with high levels of C-reactive protein in early pregnancy
have a much higher risk of spontaneous preterm birth (odds ratio
[OR] 4.64, 95% CI 0.94–22.96) [16]. Thus, antibiotic prophylaxis
to treat clinically unsuspected infection during pregnancy could,
potentially, avoid later preterm births.
Our studied pregnant populations in Malawi carry high burdens
of infective morbidity, including HIV (seropositivity 30%) [17],
malaria (33%) [9], syphilis (10% positive Treponema pallidum
haemagglutination [TPHA]), and other sexually transmitted
infections, e.g., trichomoniasis 26%, candidiasis 37% (unpublished
data). Anaemia is also common (haemoglobin,11 g/dl 72%) [18]
and attributable not only to nutritional deficiencies but also to
chronic inflammation. [19]
We hypothesised that routine antibiotic prophylaxis would
decrease the incidence of preterm labour and birth, and conducted
a placebo-controlled randomised trial of single-dose azithromycin
1 g orally at two time windows of pregnancy: 16–24 and 28–32 wk
(Text S2). Azithromycin was chosen because of its broad spectrum
of antibacterial activity including effectiveness against Ureaplasma
urealyticum (implicated as an important cause of preterm labour), its
efficacy against sexually transmitted infections including syphilis
and chlamydia, its antimalarial effects (malaria is also a cause of
prematurity), its safety profile in pregnancy [20], and the
convenience of a single oral dose with few side-effects. A recently
reported randomized trial showed that prophylactic azithromycin
reduces the risk of miscarriage after amniocentesis [21].
We also hypothesised that routine azithromycin would decrease
the incidence of malarial parasitaemia, because of its antimalarial
properties [22,23], and anaemia, because of the association of
anaemia with chronic inflammation in this population [19].
At the time of planning our study, a Cochrane systematic review
had been published on routine antibiotic administration to pregnant
women; of six randomized trials, four reported preterm delivery
rates (1,310 women) [24]. Pooled results from these diverse
populations did not show a statistically significant reduction in the
incidence of preterm delivery with prophylactic antibiotics (relative
risk 0.88, 95% CI 0.71–1.08). but the wide CIs were compatible
with a clinically important reduction in preterm birth.
Our aims were 2-fold. First, to investigate whether antibiotic
prophylaxis would be of future practical benefit in the studied
population in Malawi. Second, to test the intervention in the
population with the highest reported incidence of preterm birth—




Women were recruited from three rural and one peri-urban
antenatal clinic in Southern Malawi. Eligibility criteria were:
gestational age less than 24 wk as determined by ultrasound
(biparietal diameter measurement), intention to remain in the
study area for the duration of the pregnancy, and signed informed
consent. Biparietal diameter measurement [25] was performed by
specially trained midwives and used to calculate gestational age
(Concept 200l Dynamic Imaging). All women with confirmed
gestational age ,24 completed wk at this first visit were invited to
participate in the trial.
Recruited women were randomly allocated to either 1 g
azithromycin or placebo given at both 16–24 and 28–32 wk
gestational windows. Antenatal care was provided to all women
according to the usual schedule (planned 4-weekly visits until 32 wk;
2-weekly thereafter). At the booking visit, all women were screened
for malaria (thick film), anaemia (Hb,11 g/dl by battery operated
HemoCue device), and syphilis (VDRL). Haemoglobin and syphilis
results were available on the same day; those found positive for
syphilis were treated on the same day with intramuscular benzyl
penicillin (1 g). All women received iron tablets daily (60 mg
elemental iron as ferrous sulphate) with 0.25 mg folic acid, and
antimalarial prophylaxis (two doses of Fansidar: 500 mg sulpha-
doxine with 25 mg pyrimethamine). All azithromycin (or placebo)
and Fansidar tablets were taken under supervision at the clinic.
Women who failed to attend for their 28–32 week visit were
followed up, where possible, in the community.
Women were asked to report when they had delivered and to
return for routine visits at 1 and 6 wk postnatally; women who
withdrew from the study were followed up in an effort to obtain their
delivery date and the survival status of the woman and her neonate.
Outcome Measures
At booking and throughout antenatal care all women were
encouraged to consider voluntary counselling and testing for HIV
status, which was available in the clinic, as were antiretroviral
drugs to prevent maternal to child transmission. We did not seek to
collect prospective data about the HIV status of women. Our
objective was to determine whether routine prophylactic treatment
with an antibiotic in a population with a known high prevalence of
infection and preterm labour would reduce the incidence of
preterm labour (primary outcome). Secondary outcomes were
mean gestational age at delivery, perinatal mortality, birthweight,
and maternal malarial status and anaemia at 28–32 wk.
Preterm birth was defined as gestational age at delivery of at
least 24 wk and less than 37 wk. Perinatal mortality included
stillbirths and deaths within the first week of life.
We documented outcomes including date, type and place of
delivery, type of assistance, and condition of mother and baby. For
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babies born in a hospital or health centre, birthweight was recorded.
Babies were also weighed at postnatal visits at weeks 1 and 6.
Sample Size
Ethical approval was obtained from the College of Medicine
Research Ethics Committee (COMREC), Malawi, and permission
to work at the Health Centres was obtained from the Ministry of
Health in Malawi. The study was designed to have 90% power to
detect a reduction in the incidence of preterm birth from 20% [10]
to 15%, using a one-tailed test of significance at the 5% level. This
required 987 women per arm. To account for an anticipated 15%
dropout rate the total number recruited was to be 2,300. A one-
tailed test was planned for the primary outcome since an increase
in the incidence of preterm delivery would be of no more interest
than equivalence [26,27]. Two-tailed tests were planned for
secondary outcomes, to ensure that an impact in either direction
could be identified and reported. After agreeing to the analysis
plan, a single interim analysis was performed using a significance
level of 0.001 to avoid inflation of the final false positive error rate.
Design
The randomization schedule was prepared by a statistician not
involved in the trial analysis using a random generation procedure
with variable block size to assign both treatments equally within
Figure 1. Trial profile.
doi:10.1371/journal.pmed.1000191.g001
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each block of consecutive numbers. The azithromycin and placebo
treatments allocated were provided as identical capsules (Pfizer)
and packed in pairs of sealed envelopes for each individual study
number, according to the randomization schedule, by staff who
were not involved in the conduct of the trial. The randomization
schedule was placed in sealed envelopes and not disclosed to
anyone involved in the trial; it was only provided to the trial
statistician for the interim and final analyses.
Numbers were assigned sequentially, by the study midwives,
stratified by the two midwife teams, each serving two health
centres, at the time of enrolment to the study. Both participants
and study midwives were blinded to the study assignment. At no
time during the study was there cause to unblind the treatment
allocation for any participant.
Analysis
In accordance with the analysis plan, logistic regression was
used to estimate the effect of azithromycin on the incidence of
preterm labour, prevalence of malaria parasitaemia at the 28–32-
wk visit, and perinatal mortality. Analysis of covariance was used
to estimate the effect of azithromycin on gestational age at delivery
and on birth-weight. Variables included in these analyses as
potentially influencing outcomes were: health centre, gravidity,
body mass index (BMI), previous preterm delivery, anaemia,
malaria, and syphilis status at the week 16–24 visit. Gestational age
at delivery and multiplicity of pregnancy was also included in the
analysis of birth-weight. Gestational age at delivery was also
included (as linear and quadratic functions) in the analysis of
perinatal mortality. All analyses were performed, using Stata
software versions 9 or 10, on an intention-to-treat basis using all
available data; for all secondary outcomes two tailed tests were
performed using the 5% significance level.
An interim report, including analyses of safety and efficacy data
for the 1,151 women with an estimated date of delivery prior to 8
February 2005 was prepared for the data and safety monitoring
board in June 2005.
A limited meta-analysis was planned to include the results of this
study together with the results of other randomized trials of routine
antibiotic prophylaxis during pregnancy. These were identified
using a comprehensive search of the Cochrane Pregnancy and
Childbirth Database of Clinical Trials (details of search strategy not
included). Only the primary outcome of the APPLe (Azithromycin
for the Prevention of Preterm Labor) study (delivery,37 wk) was to
be meta-analysed (Review Manager 5; Cochrane Collaboration). A
random effects model was to be used if there was significant
heterogeneity. There were no plans for subgroup or sensitivity
analyses.
Results
Over a period of 19 mo (February 2004 to September 2005)
11,713 women were seen for their first antenatal care visit in one
of the four antenatal clinics. Of these 2,297 met the inclusion
criteria and consented to enter the trial. Of the 9,416 women not
recruited approximately 85% were more than 24 wk pregnant at
this visit and 15% were either intending to move out of the area or
did not want to join the study. The last follow-up visit was on 24
April 2006.
A trial profile is presented in Figure 1. The primary outcome
(whether delivery was preterm or not) was known for 2,183
(95.0%) women; 1,744 (75.9%) were followed up until 6 wk post
partum. The following protocol deviations occurred (Text S1): (i)
study numbers were assigned out of sequence on six occasions; (ii)
three numbers were not assigned because of study drug shortage
errors observed when opening envelopes; (iii) five women were
recruited with gestational age .24 wk during the first 5 wk of
recruitment (their gestational ages were all less than 25 wk by
ultrasound scan) and five women were recruited at ,6 wk. The
second dose was received by 1,048 (91%) of women assigned to
azithromycin and 1,056 (92%) of women assigned to placebo. 131
women received their second dose either before week 28 or after
week 32; 14 (20) assigned to azithromycin (placebo) were early by
up to 12 (30) d and 51 (46) were late by up to 20 (31) d. Two
women (both randomised to placebo) received azithromycin in
error (wrong envelope opened) at the second dose. The women for
whom these doses were intended did not receive a second dose.
Baseline characteristics were similar for the two treatment
groups (Table 1).
The overall incidence of preterm birth was 17.1% and there was
little difference between the treatment groups. The OR for
preterm birth for women given azithromycin was 0.96 (one-sided
95% upper confidence limit: 1.21). Likewise, no statistically
significant difference was found between the treatment arms for
any of the secondary outcomes (Table 2). Although not
prespecified as an outcome, there was also no statistically
significant difference (Fisher’s exact, p=0.38) between the
treatment arms in the incidence of early preterm birth
(,34 wk): azithromycin (4.6%), placebo (5.4%).
Meta-analysis of the results of eight trials of routine antibiotic
prophylaxis, including APPLe, using a random effects model,
showed the relative risk of preterm birth (,37 wk) with routine
prophylactic antibiotics to be 1.02 (95% CI 0.86–1.22) (Figure 2).
Discussion
The overall incidence of preterm birth in our trial was 17.1%,
which is higher than the figure reported in other populations, and
which is not dissimilar to the findings of our previous, smaller
study (incidence 20%; 95% CI 17%–24%) that formed the basis
for the sample size calculation [10]. The incidence of preterm
birth was the same for the two groups and our trial provided no
support for our hypothesis that this regimen of prophylactic
Table 1. Baseline comparability of randomised groups by
treatment group.
Variable Statistic/Category Treatment Group
Azithromycin Placebo
Number of women — 1,149 1,148
Gestational age at
booking (wk)
Mean (sd) 20.7 (2.1) 20.7(2.2)
Maternal age (y) Mean (sd) 22.8 (5.1) 23.0 (5.2)
Gravidity 1 416 (36.2%) 397 (34.6%)
2–4 581 (50.6%) 581 (50.6%)
$5 152 (13.2%) 170 (14.8%)
Weight for height
(kg/m2)
Mean (sd) 22.7 (2.5) 22.7 (2.7)
Syphilis status
(VDRL + ve)
— 81 (7.1%) 82 (7.1%)
Haemoglobin (g/dl) Mean (sd) 10.7 (1.7) 10.8 (1.7)
Positive malaria slide — 298 (25.9%) 274 (23.9%)
sd, standard deviation; VDRL, venereal disease research laboratory; + ve,
positive.
doi:10.1371/journal.pmed.1000191.t001
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azithromycin would reduce the incidence of preterm birth and
improve outcome.
Some researchers use early preterm birth (e.g., ,34 wk) as their
main outcome measure as neonatal mortality is higher after early
preterm than late preterm birth. We chose, as the primary
outcome, overall preterm birth (,37 wk) because our previous
studies had shown high rates of perinatal mortality (160/1,000)
associated with late preterm birth (33–36 wk) in this population
[10]. In addition, morbidity is greater after late preterm than term
birth, even in high income communities [28]. Azithromycin was,
in any case, not shown in the current study to be effective in
preventing early, as well as overall, preterm birth.
As far as we are aware, our studied population of unselected
pregnant women in a rural population in sub-Saharan Africa is
unique in having had the gestational ages of their pregnancies
confirmed by ultrasound. Gestational dating by clinical examina-
tion in later pregnancy or by the date of the last menstrual period
is unreliable. Many studies in low-income countries have therefore
used ‘‘low birthweight’’ (,2.5 kg) as a surrogate for preterm
birth—but it is a poor surrogate as low birthweight babies may be
either small-for-gestational age at term or preterm. We are
currently studying the mortality and morbidity and developmental
outcome of these babies, with known gestational age at birth.
It has been convincingly argued that the results of clinical trials
should be discussed against the background of the totality of
evidence from other similar studies [29,30]. Since the publication
of the Cochrane review [24] that incorporated data from four
studies [31–34], results from an additional four trials of routine
antibiotic prophylaxis with preterm birth as an outcome have
become available [35–37], including APPLe (Table 3). The largest
trials, by far, are APPLe and HPTN 024. HPTN 024 was, like
APPLe, performed in central Africa but relied, unlike APPLe, on
menstrual dates and clinical examination rather than ultrasound for
gestational age assessment [37,38]. The eight trials took place in
diverse settings (high and low income), with different types of
participants (e.g., unselected women, women at high risk of preterm
birth by past histories, women who were predominantly HIV
positive), differing timings of treatment, and different antibiotic
regimens. As well as clinical heterogeneity, there was statistical
heterogeneity on analysis of the pooled data (I2, 51%) from, overall,
Table 2. Summary and comparison of outcomes by treatment group.
Treatment Group Treatment Group p-Value* Mean Difference or ORa 95% CI
Azithromycin Placebo
Number (%) who had preterm birth 184/1,096 (16.8%) 189/1,087 (17.4%) 0.75 (0.71) 0.96b (,1.21)c
Mean gestational age (wk) at delivery 38.5 (n= 1,091) 38.4 (n= 1,081) 0.18 (0.16) 0.16d (20.08 to 0.40)
Mean birthweight (kg) 3.03 (n= 769) 2.99 (n= 739) 0.08 (0.14) 0.04d (20.005 to 0.08)
n (%) at 2nd dose with malaria parasitaemia 117/1,014 (11.5%) 103/1,017 (10.1%) 0.46 (0.31) 1.11b 0.84–1.49
n (%) at 2nd dose with anaemiae 445/1,010 (44.1%) 418/1,017 (41.3%) 0.48 (0.24) 1.07b 0.88–1.30
n (%) of perinatal deaths 45/1,051 (4.3%) 51/1,035 (5.0%) 0.52 (0.48) 0.85b (0.53–1.38)
Thirteen maternal deaths were reported; three occurred during pregnancy (one in the azithromycin group) and ten within 6 wk of delivery (seven in the azithromycin
group). Adverse events were reported for three other women (vomiting after taking medication), of whom two were in the azithromycin group. The event rates for
these deaths and adverse events were too low for statistical comparisons to be appropriate.
aDerived from multivariable analyses using women with available data.
bOR.
cOne-sided 95% CI as specified in the analysis plan.
dMean difference.
eThis analysis was not specified in the analysis plan.
*p-Values for univariable analyses are given in parentheses.
doi:10.1371/journal.pmed.1000191.t002
Figure 2. Random effects meta-analysis of trials of routine antibiotic prophylaxis in pregnancy that report preterm birth,37 wk as
outcome.
doi:10.1371/journal.pmed.1000191.g002
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6,228 pregnancies. Meta-analysis, using a random effects model
showed the relative risk of preterm birth (,37 wk) with routine
prophylactic antibiotics to be 1.02 (95% CI 0.86–1.22).
It is important to try to reconcile this finding that routine
antibiotic prophylaxis does not prevent preterm birth, with the
considerable observational data that associates infection with
preterm labour. It is possible that different antibiotics or different
antibiotic regimens with more intensive treatment schedules might
impact on preterm birth rates. However, more complicated
antibiotic regimens would have less appeal in resource-poor settings.
Another explanation is that ascending intrauterine infection
may have been overemphasised as a primary cause of preterm
birth. If factors such as psychosocial stress or heavy work, for
example, are important in the premature triggering of the
placental corticotropin-releasing hormone (CRH) pathway that
ultimately leads to parturition [12], associated premature cervical
shortening and dilatation might permit secondary ascending
bacterial invasion of the uterine cavity. This has been suggested
in the past [39] in the context of twin pregnancy in which preterm
birth is common, and early cervical dilatation does occur [40].
Transvaginal ultrasound scanning has shown short cervices to be a
powerful predictor of preterm birth in singleton pregnancies [41].
At the time of planning of the trial, it was assumed that
antibiotic prophylaxis during pregnancy was unlikely to confer any
harm, whether or not it conferred any benefit. The publication of
the follow-up of the ORACLE trial has shown that this assumption
was wrong. This report showed that children of women treated
with antibiotics for preterm labour (not prophylactically) were
more likely to have neuro-developmental delay [42]. Our study
adds further weight to the conclusion that pregnant women should
not be treated with antibiotics unless for specific infections and
with good evidence of likely benefit.
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DOC)
Text S2 CONSORT checklist.
Found at: doi:10.1371/journal.pmed.1000191.s002 (0.06 MB
DOC)
Acknowledgments
The data monitoring panel was P.A. Williamson and M. Turner. The
HPTN024 trial team provided unpublished, pooled data on gestational age
at delivery, for the meta-analysis. The late Tony Hart gave valuable advice
in the planning of the study.
George Kafulafula died on 28 August 2009.
Author Contributions
ICMJE criteria for authorship read and met: NRvdB SAW MG CN GK
JPN. Agree with the manuscript’s results and conclusions: NRvdB SAW
MG CN EK GK JPN. Designed the experiments/the study: NRvdB JPN.
Analyzed the data: NRvdB SAW. Collected data/did experiments for the
study: NRvdB CN EK. Enrolled patients: CN EK. Wrote the first draft of
the paper: NRvdB JPN. Contributed to the writing of the paper: SAW CN
EK GK. NvdB and JPN planned the study. With SAW, they wrote the
analysis plan and wrote the first draft of the manuscript. JPN performed the
meta- analysis. MG, CN, and GK managed the project in Malawi. CN and
EK managed the teams of research midwives in Malawi and performed the
ultrasound scans.
References
1. Lawn JE, Cousens S, Zupan J for the Lancet Neonatal Survival Steering Team
(2005) 4 million neonatal deaths: When? Where? Why? Lancet 365: 891–900.
2. Jones GRW, Steketee RE, Black RE, Bhutta ZA, Morris SS and the Bellagio
Child Survival Group (2003) How many child deaths can we prevent this year?
Lancet 362: 65–71.
3. Martines J, Paul VK, Bhutta ZA for the Lancet Neonatal Survival Steering
Team (2005) Neonatal survival: a call for action. Lancet 365: 1189–1197.
4. Eichenwald EC, Stark AR. Management and outcomes of very low birth weight
(2008) New Eng J Med 358: 1700–1711.
5. Steer P (2005) The epidemiology of preterm labour. BJOG 112: s1–s3.
6. Langhoff-Roos J, Kesmodel U, Jacobsson B, Rasmussen S, Vogel I (2006)
Spontaneous preterm delivery in primiparous women at low risk in Denmark:
population based study. BMJ 332: 937–939.
7. Shennan AH, Bewley S (2006) Why should preterm births be rising? BMJ 332:
924–925.
8. Hoyert DL, Mathews TJ, Menacker F, Strobino DM, Guyer B (2006) Annual
summary of vital statistics: 2004. Pediatrics 117: 168–183.
9. van den Broek NR, White SA, Flowers C, Cook JD, Letsky EA, et al. (2006)
Randomised trial of vitamin A supplementation in pregnant women in rural
Malawi found to be anaemic on screening by HemoCue. BJOG 113: 569–
576.
10. van den Broek NR, Ntonya C, Kayira E, White S, Neilson JP (2005) Preterm
birth in rural Malawi: high incidence in ultrasound-dated population. Hum
Reprod 20: 3235–3237.
11. Challis K, Osman NB, Nystrom L, Nordahl G, Bergstrom S (2002) Symphysis-
fundal height growth chart of an obstetric cohort of 817 Mozambican women
with ultrasound-dated singleton pregnancies. Trop Med Int Health 7: 678–684.
12. Smith R (2007) Parturition. New Eng J Med 356: 271–283.
13. Simhan HN, Caritis SN (2007) Prevention of preterm delivery. New Eng J Med
357: 477–487.




McGregor 1990 [31] USA 235 unselected women 26–30 Erythromycin versus placebo
Hauth 1995 [32] USA 624 women at high risk of preterm birth 22–24 Metronidazole + erythromycin versus
placebo
Vermeulen 1995 [33] Holland 168 women with history of preterm birth 26–32 Vaginal clindamycin versus placebo
Paul 1997 [34] India 437 unselected women 26–34 Erythromycin versus placebo
Sen 2005 [35] India 224 unselected ‘‘urban poor’’ 14–24 Metronidaxzole + cephalexin versus no
treatment
Shennan 2006 [36] UK 100 high risk women with +ve fetal fibronectin 24–27 Metronidazole versus placebo
Goldenberg 2006 [37,38] Zambia, Malawi,
Tanzania
2,098 HIV+ and 335 HIV2 women 20–24 Metronidazole + erythromycin versus
placebo
APPLe Malawi 2,297 unselected women 16–24 and 28–32 Azithromycin versus placebo
doi:10.1371/journal.pmed.1000191.t003
Azithromycin to Prevent Preterm Birth
PLoS Medicine | www.plosmedicine.org 6 December 2009 | Volume 6 | Issue 12 | e1000191
14. Goldenberg RL, Hauth JC, Andrews WW (2000) Intrauterine infection and
preterm delivery. New Eng J Med 342: 1500–1507.
15. Goldenberg RL, Culhane JF, Iams JD, Romero R (2008) Epidemiology and
causes of preterm birth. Lancet 371: 75–84.
16. Pitiphat W, Gillman WW, Joshipura KJ, Williams PL, Douglass CW, et al.
(2005) Plasma C-reactive protein in early pregnancy and preterm delivery.
Am J Epidemiol 162: 1108–1113.
17. van den Broek NR, White SA, Neilson JP (1998) The relationship between
asymptomatic human immunodeficiency virus infection and the prevalence and
severity of anaemia in pregnant Malawian women, Am J Trop Med Hyg 59:
1004–1007.
18. van den Broek NR, Rogerson S, Mhango CG, Bambala B, White SA, et al.
(2000) Anaemia in pregnancy in southern Malawi: prevalence and risk factors.
BJOG 107: 445–451.
19. van den Broek NR, Letsky EA (2000) Etiology of anemia in pregnancy in south
Malawi. Am J Clin Nutr 72(suppl): 247S–256S.
20. Sarkar M, Woodland CC, Koren G, Einarson ARN (2006) Pregnancy outcome
following exposure to azithromycin. BMC Pregnancy and Childbirth 6: 18.
21. Giorlandino C, Cignini P, Cini M, Brizzi C, Carcioppolo O, et al. (2009)
Antibiotic prophylaxis before second-trimester genetic amniocentesis (APGA): a
single-centre open randomized controlled trial. Prenat Diagn. DOI: 10.1002/
pd.2256.
22. Chico RM, Pittrof R, Greenwood B, Chandramohan D (2008) Azithromycin-
chloroquine and the intermittent preventive treatment of malaria in pregnancy.
Malaria Journal 7: 255.
23. Kalilani L, Mofolo I, Chaponda M, Rogerson SJ, Alker AP, et al. (2007) A
randomized controlled trial of azithromycin or artesunate added to sulfadoxine-
pyrimethamine as treatment for malaria in pregnant women. PLoS ONE 2:
e1166. doi:10.1371/journal.pone.0001166.
24. Thinkhamrop J, Hofmeyr GJ, Adetoro O, Lumbiganon P (2002) Prophylactic
antibiotic administration in pregnancy to prevent infectious morbidity and
mortality. Cochrane Database Sys Rev CD 002250.
25. Chitty LS, Altman DG, Henderson A, Campbell S (1994) Charts of fetal size: 2
Head measurements. BJOG 101: 35–43.
26. Bland JM, Altman DG (1994) One and two sided tests of significance. BMJ 309:
248.
27. Overall JE (1991) A comment concerning one-sided tests of significance in new
drug applications. J Biopharm Stat 1: 157–160.
28. Saigal S, Doyle LW (2008) An overview of mortality and sequelae of preterm
birth from infancy to adulthood. Lancet 371: 261–269.
29. Young C, Horton R (2005) Putting clinical trials into context. Lancet 366:
107–108.
30. Clarke M, Hopewell S, Chalmers I (2007) Reports of clinical trials should begin
and end with up-to-date systematic reviews of other relevant evidence: a status
report. J R Soc Med 100: 187–190.
31. McGregor JA, French JI, Richter R, Vuchetich M, Bachus V, et al. (1990)
Cervicovaginal microflora and pregnancy outcome: results of a double-blind,
placebo-controlled trial of erythromycin treatment. Am J Obstet Gynecol 163:
1580–1591.
32. Hauth JC, Goldenberg LR, Andrews WW, DuBard MB, Copper RL (1995)
Reduced incidence of preterm delivery with metronidazole and erythromycin in
women with bacterial vaginosis. N Eng J Med 333: 1732–1736.
33. Vermeulen GM, Bruinse HW (1999) Prophylactic administration of clindamycin
2% vaginal cream to reduce the incidence of spontaneous preterm birth in
women with an increased recurrence risk: a randomised placebo-controlled trial
double-blind trial. BJOG 106: 652–657.
34. Paul VK, Singh M, Buckshee K (1998) Erythromycin treatment of pregnant
women to reduce the incidence of low birth weight and preterm deliveries.
Int J Gynecol Obstet 62: 87–88.
35. Sen A, Mahalanabis D, Mukhopadhyay S, Chakrabarty K, Singh AK, et al.
(2005) Routine use of antimicrobials by pregnant Indian women does not
improve birth outcome: a randomized controlled trial. J Health Popul Nutr 23:
236–244.
36. Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, et al. (2006) A
randomised controlled trial of metronidazole for the prevention of preterm birth
in women positive for cervicovaginal fetal fibronectin: the PREMET study.
BJOG 113: 65–74.
37. Taha TE, Brown ER, Hoffman IF, Fawzi W, Read JS, et al. (2006) A phase III
clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1
transmission. AIDS 20: 1313–1321.
38. Goldenberg RL, Mwatha A, Read JS, Adeniyi-Jones S, Sinkala M, et al. (2006)
The HPTN 024 study: the efficacy of antibiotics to prevent chorioamnionitis and
preterm birth. Am J Obstet Gynecol 194: 650–661.
39. Romero R, Shamma F, Jimenez C, Callahan R, Nores J, et al. (1990) Infection
and labor VI. Prevalence, microbiology, and clinical significance of intraamnio-
tic infection in twin gestations with preterm labor. Am J Obstet Gynecol 163:
757–761.
40. Neilson JP, Verkuul DAA, Crowther CA, Bannerman C (1988) Preterm labor in
twin pregnancies: prediction by cervical assessment. Obstet Gynecol 72:
719–723.
41. Honest H, Bachman LM, Coomarasamy A, Gupta JK, Kleijnen J, et al. (2003)
Accuracy of cervical sonography in predicting preterm birth: a systematic
review. Ultrasound Obstet Gynecol 22: 305–322.
42. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, et al. (2008) Childhood
outcomes after prescription of antibiotics to pregnant women with spontaneous
preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 372:
1319–1327.
Azithromycin to Prevent Preterm Birth
PLoS Medicine | www.plosmedicine.org 7 December 2009 | Volume 6 | Issue 12 | e1000191
Editors’ Summary
Background. Most pregnancies last about 40 weeks. Labor
that occurs before 37 weeks of gestation (the period during
which a baby develops in its mother) is defined as a preterm
birth. In industrialized countries, 5%–10% of all births are
preterm. Figures for preterm births are harder to obtain for
low-income countries because of uncertainties about
gestational dates but, in both rich and poor countries,
preterm birth is a major cause of infant death and illness
around the time of birth. Babies who are born prematurely
also often have long-term health problems and disabilities.
There are many reasons why some babies are born
prematurely. Structural problems such as a weak cervix
(the neck of the womb, which dilates during labor to allow
the baby to leave the mother’s body) can result in a
premature delivery, as can pregnancy-induced diabetes,
blood-clotting disorders, bacterial infections in the vagina
or the womb, and malaria. However, it is impossible to
predict which mothers will spontaneously deliver early.
Why Was This Study Done? At present there is no
effective way to prevent premature births. Because infection
is often associated with preterm labor and can occur early in
pregnancy but remain undetected, one way to reduce the
incidence of preterm births may be to give pregnant women
antibiotics even when they have no obvious infection
(prophylactic antibiotics). In this study, the researchers test
this hypothesis by giving the antibiotic azithromycin to
pregnant women living in Southern Malawi in a randomized,
placebo-controlled trial. One baby in five is born before 37
weeks gestation in Southern Malawi and the women living in
this part of sub-Saharan Africa have a high burden of
infection. Azithromycin is a safe antibiotic that can treat
many of the bacterial infections that have been implicated in
preterm birth. It also has some antimalarial activity. In a
randomized, placebo-controlled trial, participants are
randomly assigned to receive a drug or identical-looking
‘‘dummy’’ tablets (placebo).
What Did the Researchers Do and Find? The researchers
enrolled more than 2,000 pregnant women into the APPLe
study (Azithromycin for the Prevention of Preterm Labor)
and determined the gestational age of their unborn babies
using ultrasound. Half of the women were given an oral dose
of azithromycin at 16–24 weeks and at 28–32 weeks
gestation. The remaining women were given a placebo at
similar times. The mothers and their babies were followed up
until 6 weeks after delivery. There was no significant
difference in the primary outcome of the study—the
incidence of delivery before 37 weeks gestation—between
the two groups of women. Secondary outcomes—including
mean gestational age at delivery, mean birth weight, and still
births and infant deaths within a week of birth—were also
similar in the two groups of women. Finally, the researchers
did a meta-analysis (a statistical technique that combines the
results of several studies) of their study and seven published
studies of routine antibiotic prophylaxis in pregnancy, which
indicated that the prophylactic use of antibiotics did not
alter the risk of preterm birth.
What Do These Findings Mean? These findings provide
no support for the use of antibiotics as prophylaxis to
prevent preterm birth. The women included in this study had
an unusually high incidence of preterm delivery and a high
burden of infection so these findings may not be
generalizable. The results of the meta-analysis, however,
also provide no support for prophylactic antibiotics. Given
that observational data have associated infection with
preterm labor, why are the results of the APPLe trial and
the meta-analysis negative? One possibility is that different
antibiotics or dosing regimens might be more effective.
Another possibility is that infection might be a secondary
consequence of some other condition that causes preterm
birth rather than the primary cause of early delivery.
Whatever the reason for the lack of effect of prophylactic
antibiotics, the researchers recommend that pregnant
women should not be given antibiotics prophylactically to
prevent preterm birth particularly since, in a recent study,
the babies of women given antibiotics to halt ongoing
preterm labor had an increased risk of developmental
problems.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000191.
N The March of Dimes, a nonprofit organization for
pregnancy and baby health, provides information on
preterm birth (in English and Spanish)
N The Nemours Foundation, another nonprofit organization
for child health, also provides information on premature
babies (in English and Spanish)
N Tommy’s is a nonprofit organization that funds research
and provides information on the causes and prevention of
miscarriage, premature birth, and stillbirth
N The US Centers for Disease Control and Prevention
provides information on maternal and infant health (in
English and Spanish)
N The US National Women’s Health Information Center has
detailed information about pregnancy (in English and
Spanish)
N MedlinePlus provides links to other information on
premature babies (in English and Spanish)
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